- Home
- CPSS vs SLS Comparison
CPSS vs SLS Comparison
Compare CPSS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPSS
- SLS
- Stock Information
- Founded
- CPSS 1991
- SLS 2012
- Country
- CPSS United States
- SLS United States
- Employees
- CPSS N/A
- SLS N/A
- Industry
- CPSS Finance: Consumer Services
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- CPSS Finance
- SLS Health Care
- Exchange
- CPSS Nasdaq
- SLS Nasdaq
- Market Cap
- CPSS 193.8M
- SLS 169.6M
- IPO Year
- CPSS 1992
- SLS N/A
- Fundamental
- Price
- CPSS $9.05
- SLS $1.71
- Analyst Decision
- CPSS
- SLS
- Analyst Count
- CPSS 0
- SLS 0
- Target Price
- CPSS N/A
- SLS N/A
- AVG Volume (30 Days)
- CPSS 12.5K
- SLS 3.0M
- Earning Date
- CPSS 05-12-2025
- SLS 05-13-2025
- Dividend Yield
- CPSS N/A
- SLS N/A
- EPS Growth
- CPSS N/A
- SLS N/A
- EPS
- CPSS 0.79
- SLS N/A
- Revenue
- CPSS $188,776,000.00
- SLS N/A
- Revenue This Year
- CPSS $146.82
- SLS N/A
- Revenue Next Year
- CPSS $18.24
- SLS N/A
- P/E Ratio
- CPSS $11.45
- SLS N/A
- Revenue Growth
- CPSS N/A
- SLS N/A
- 52 Week Low
- CPSS $7.85
- SLS $0.77
- 52 Week High
- CPSS $12.73
- SLS $2.12
- Technical
- Relative Strength Index (RSI)
- CPSS 50.84
- SLS 54.26
- Support Level
- CPSS $8.68
- SLS $1.36
- Resistance Level
- CPSS $8.99
- SLS $2.12
- Average True Range (ATR)
- CPSS 0.31
- SLS 0.18
- MACD
- CPSS -0.01
- SLS -0.01
- Stochastic Oscillator
- CPSS 34.03
- SLS 46.05
About CPSS Consumer Portfolio Services Inc.
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.